Skip to content

MBX Biosciences, Inc. MBX Total Operating Expenses

Total Operating Expenses at other companies

Viking Therapeutics logo
Viking TherapeuticsVKTX
$164.13M+196%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$98.75M+21.4%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$112.33M+40.0%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$115.1M+36.4%
Arrowhead Research logo
Arrowhead ResearchARWR
$215M+33.1%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$60.02M+26.0%

Other financials

Income statement

See full
Operating income-$27.3M-2.8%
Net income-$23.5M+1.5%
EPS (diluted)-$0.50+29.6%

Balance sheet

See full
Cash & equivalents$45.2M+51.2%
Total debt$555.0K+327%
Total equity$437.8M+85.9%
Total assets$452.7M+84.1%

Cash flow

See full
Operating cash flow-$20.2M+10.9%
CapEx$437.0K+1,357%
Free cash flow-$20.6M+9.1%

Valuation

See full
Market cap$2.21B+475%
Enterprise value$2.16B+533%

Returns & leverage

See full
Return on equity-25.7%
Debt / equity0.0×
Current ratio30.8×+7.5×

Where this comes from

Reported directly by MBX Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The official record: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about MBX Biosciences, Inc.'s total operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MBX Biosciences, Inc.'s total operating expenses?
MBX Biosciences, Inc. (MBX) reported total operating expenses of $27.27M in Q1 2026.
How has MBX Biosciences, Inc.'s total operating expenses changed year-over-year?
MBX Biosciences, Inc.'s total operating expenses increased by 2.8% year-over-year, from $26.53M to $27.27M.
What does total operating expenses mean?
The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.